Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Authors
Keywords
Regorafenib, Avelumab, Biliary tract cancer, Immunotherapy, Cholangiocarcinoma
Journal
EUROPEAN JOURNAL OF CANCER
Volume 162, Issue -, Pages 161-169
Publisher
Elsevier BV
Online
2022-01-06
DOI
10.1016/j.ejca.2021.11.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Angiogenesis in biliary tract cancer: targeting and therapeutic potential
- (2021) Margherita Rimini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.
- (2021) Shalini Makawita et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN
- (2020) A. Demols et al. ANNALS OF ONCOLOGY
- A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
- (2020) Richard D. Kim et al. CANCER
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
- (2020) Robert Montal et al. JOURNAL OF HEPATOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
- (2020) Soomin Ahn et al. Scientific Reports
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- (2019) Tanios S Bekaii-Saab et al. LANCET ONCOLOGY
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
- (2018) Brian W. Labadie et al. CLINICAL CANCER RESEARCH
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
- (2016) Kulthida Vaeteewoottacharn et al. TUMOR BIOLOGY
- Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
- (2015) A. Moeini et al. CLINICAL CANCER RESEARCH
- Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma
- (2014) Hiroyuki Takahashi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
- (2013) Daniela Sia et al. GASTROENTEROLOGY
- Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
- (2011) Hiroaki Sugiyama et al. JOURNAL OF GASTROENTEROLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
- (2009) D Yoshikawa et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial
- (2007) Sarah Zohar et al. Contemporary Clinical Trials
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation